B7-H3.CAR-BBz-T

B7-H3.CAR-BBz-T is a chimeric antigen receptor (CAR) T-cell therapy engineered to target B7-H3 (CD276), a transmembrane protein and immune checkpoint molecule that is highly overexpressed in a wide range of pediatric and adult solid tumors, including neuroblastoma, osteosarcoma, and pancreatic cancer. The CAR construct consists of a B7-H3-specific single-chain variable fragment (scFv) linked to a 4-1BB (CD137) co-stimulatory domain and a CD3ζ signaling domain. The incorporation of the 4-1BB domain is designed to enhance T-cell metabolic fitness, promote long-term persistence, and reduce exhaustion markers like PD-1, which is particularly advantageous for treating solid tumors with immunosuppressive microenvironments. Preclinical studies have demonstrated that B7-H3.CAR-BBz-T cells can effectively control tumor growth in various xenograft models without significant off-tumor toxicity, leading to its evaluation in Phase 1 clinical trials.

Other names

B7-H3 CAR-TB-7-H3 CAR-TB 7-H3 CAR-TCD276 CAR-TCD-276 CAR-TCD 276 CAR-TB7-H3-directed 4-1BB-costimulated CAR-T cellsB-7-H3-directed 4-1BB-costimulated CAR-T cellsB 7-H3-directed 4-1BB-costimulated CAR-T cells